Inceptor Bio has filed a notice of an exempt offering of securities to raise $3,400,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Inceptor Bio is raising up to $3,400,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Inceptor Bio
Inceptor Bio is developing multiple next-generation cell therapy platforms to cure difficult-to-treat cancers with a focus on novel mechanisms to enhance immune cell performance in the tumor microenvironment. To achieve this goal, we assembled a purpose-driven team, recruiting pioneers in oncology, gene therapy, cell therapy and gene editing to join our mission. We provide a unique partnership model to university research programs focused on cutting-edge therapeutic approaches for oncology. The combination of our lab and manufacturing resources with the industry experience of our cell and gene therapy experts will advance therapeutics into the clinic with remarkable efficiency.
To learn more about Inceptor Bio, visit http://www.inceptor.bio/
Inceptor Bio Linkedin Page: https://www.linkedin.com/company/inceptor-bio/
Contact:
Shailesh Maingi, Chief Executive Officer
919-521-6400
https://www.linkedin.com/in/shaileshmaingi/
SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.